ÌÇÐÄvlog

[Skip to Navigation]
Sign In

October 2024 - April 2016

Decade

Year

Issue

July 2021, Vol 6, No. 7, Pages 739-855

Original Investigation

Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening

Abstract Full Text
free access
JAMA Cardiol. 2021;6(7):745-752. doi:10.1001/jamacardio.2021.0565

This cross-sectional study compiles data from multiple North American professional sports teams to assess the prevalence of detectable inflammatory heart disease in professional athletes with prior coronavirus disease 2019 infection.

Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial

Abstract Full Text
free access
JAMA Cardiol. 2021;6(7):753-761. doi:10.1001/jamacardio.2021.0475

This randomized clinical trial evaluates the efficacy and safety of revacept, a novel, lesion-directed antithrombotic drug, acting as a competitive antagonist to platelet glycoprotein VI.

Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling After Myocardial Infarction: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Cardiol. 2021;6(7):762-768. doi:10.1001/jamacardio.2021.0676

This randomized clinical trial assesses whether inhibition of calcium/calmodulin-dependent protein kinase II delta after myocardial infarction prevents left ventricular remodeling.

Cardiovascular Biomarkers in the Early Discrimination of Type 2 Myocardial Infarction

Abstract Full Text
free access
JAMA Cardiol. 2021;6(7):771-780. doi:10.1001/jamacardio.2021.0669

This international, multicenter prospective diagnostic study tests whether novel cardiovascular biomarkers quantifying different pathophysiological pathways involved in type 2 and/or type 1 myocardial infarction may aid physicians in the rapid discrimination of these 2 types of myocardial infarction.

Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease

Abstract Full Text
free access
JAMA Cardiol. 2021;6(7):782-790. doi:10.1001/jamacardio.2021.0683

This study evaluates sex-based differences in antiplatelet agents, any statin, high-intensity statin therapy, and statin adherence in patients with premature and extremely premature atherosclerotic cardiovascular disease.

Association of Dual Eligibility for Medicare and Medicaid With Heart Failure Quality and Outcomes Among Get With The Guidelines–Heart Failure Hospitals

Abstract Full Text
free access
JAMA Cardiol. 2021;6(7):791-800. doi:10.1001/jamacardio.2021.0611

This cohort study evaluates the association between the proportion of dual-eligible beneficiaries for Medicare and Medicaid with heart failure quality of care and outcomes.

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
free access
JAMA Cardiol. 2021;6(7):801-810. doi:10.1001/jamacardio.2021.0660

This secondary analysis of a randomized clinical trial evaluates the relative safety and efficacy of dapagliflozin vs placebo by assessing risks of a composite of cardiovascular death and hospitalization for heart failure and of major adverse cardiovascular events according to baseline estimated glomerular filtration rate and urinary albumin to creatinine ratio in patients with type 2 diabetes.

Association of Rare Genetic Variants and Early-Onset Atrial Fibrillation in Ethnic Minority Individuals

Abstract Full Text
free access has audio
JAMA Cardiol. 2021;6(7):811-819. doi:10.1001/jamacardio.2021.0994

This cohort study describes comprehensive sequencing of 60 candidate atrial fibrillation genes in African American and Hispanic/Latinx probands to examine the combined prevalence of rare pathogenic variants and assess genotype-phenotype associations.

Association of Systolic Blood Pressure Elevation With Disproportionate Left Ventricular Remodeling in Very Preterm-Born Young Adults: The Preterm Heart and Elevated Blood Pressure

Abstract Full Text
open access
JAMA Cardiol. 2021;6(7):821-829. doi:10.1001/jamacardio.2021.0961

This study investigates whether changes observed in left ventricular structure and function in preterm-born adults make them more susceptible to cardiac remodeling in association with blood pressure elevation.

Brief Report

Remote Postdischarge Treatment of Patients With Acute Myocardial Infarction by Allied Health Care Practitioners vs Standard Care: The IMMACULATE Randomized Clinical Trial

Abstract Full Text
open access
JAMA Cardiol. 2021;6(7):830-835. doi:10.1001/jamacardio.2020.6721

This randomized clinical trial compares the safety and efficacy of nurse practitioner–led remote intensive management with cardiologist-led standard care for low-risk patients with acute myocardial infarction.

Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial

Abstract Full Text
free access
JAMA Cardiol. 2021;6(7):836-840. doi:10.1001/jamacardio.2020.6827

This exploratory post hoc analysis of a randomized clinical trial examined the outcomes of empagliflozin vs placebo on cardiac remodeling in patients with heart failure with reduced ejection fraction.

Identification of Cardiac Fibrosis in Young Adults With a Homozygous Frameshift Variant in SERPINE1

Abstract Full Text
free access
JAMA Cardiol. 2021;6(7):841-846. doi:10.1001/jamacardio.2020.6909

This multimodality study reports a detailed cardiovascular phenotyping and genotyping in young adults from an Amish family with a frameshift variant (c.699_700dupTA) in SERPINE1, the gene that codes for plasminogen activator inhibitor-1.

Research Letter

Prevalence of Hypertrophic Cardiomyopathy in the UK Biobank Population

Abstract Full Text
open access
JAMA Cardiol. 2021;6(7):852-854. doi:10.1001/jamacardio.2021.0689

This cohort study examines the prevalence of hypertrophic cardiomyopathy in the UK Biobank population.

Viewpoint

Could Flozins Be the Statins for Risk-Based Primary Prevention of Heart Failure?

Abstract Full Text
JAMA Cardiol. 2021;6(7):741-742. doi:10.1001/jamacardio.2021.1133

This Viewpoint synthesizes available data for the role of sodium-glucose cotransporter-2 inhibitor in heart failure and proposes a theoretical framework to evaluate flozins in primary prevention of heart failure akin to the role of statins in atherosclerotic cardiovascular disease.

Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed

Abstract Full Text
JAMA Cardiol. 2021;6(7):743-744. doi:10.1001/jamacardio.2021.0496

This Viewpoint advocates for expanded use of quadruple therapy in patients with heart failure with reduced ejection fraction.

Invited Commentary

To Be or Not to Be a CaMKII Inhibitor?

Abstract Full Text
JAMA Cardiol. 2021;6(7):769-770. doi:10.1001/jamacardio.2021.0701
JAMA Cardiology Clinical Challenge

A Young Patient With Hives and Chest Pain

Abstract Full Text
JAMA Cardiol. 2021;6(7):847-848. doi:10.1001/jamacardio.2021.0749

A patient in their 20s presents with an anaphylactic reaction complicated by hypotension and chest pain on administration of epinephrine. What would you do next?

JAMA Cardiology Diagnostic Test Interpretation

Transthyretin Genetic Testing

Abstract Full Text
JAMA Cardiol. 2021;6(7):849-850. doi:10.1001/jamacardio.2021.0835

A 40-year-old woman with a pathogenic variant in the transthyretin gene has a single heterozygous nucleotide variant leading to substitution of serine for tyrosine at amino acid position 97. She has a history of carpel tunnel syndrome, no family history of amyloidosis, and physical examination results that include a blood pressure of 112/76 mm Hg and a heart rate of 79/min. Her cardiovascular results are unremarkable. What would you do next?

Comment & Response

Statin Prescribing and Dosing—Failure Has Become an Option

Abstract Full Text
JAMA Cardiol. 2021;6(7):854-855. doi:10.1001/jamacardio.2021.0832

Statin Prescribing and Dosing—Failure Has Become an Option—Reply

Abstract Full Text
JAMA Cardiol. 2021;6(7):855. doi:10.1001/jamacardio.2021.0838
Editor's Note

Differentiating Type 1 and Type 2 Myocardial Infarction: Unfortunately, Still More Art Than Science

Abstract Full Text
JAMA Cardiol. 2021;6(7):781. doi:10.1001/jamacardio.2021.0693

Genetic Studies of Atrial Fibrillation in Diverse Cohorts and Identification of Diverse Phenotypes Associated With Single Genes

Abstract Full Text
has audio
JAMA Cardiol. 2021;6(7):820. doi:10.1001/jamacardio.2021.1004
Correction

Error in Author Name

Abstract Full Text
free access
JAMA Cardiol. 2021;6(7):855. doi:10.1001/jamacardio.2021.2813
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2021;6(7):739. doi:10.1001/jamacardio.2020.4564
×